Skip to content

INTENSITY THERAPEUTICS, INC.

INTS

CIK 0001567264 · Biological Products, (No Diagnostic Substances) · Nasdaq

Revenue (TTM)
Q1 May 2026
Net Income (TTM)
−$10.99M
+28.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.66
+70.7% YoY Q1 May 2026
Gross Margin
Q1 May 2026
Operating Margin
Q1 May 2026
Net Margin
Q1 May 2026
Free Cash Flow (TTM)
Q1 May 2026
Cash
$10.25M
Q1 May 2026
Total Debt
Q1 May 2026
Shares Outstanding
2.7M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings